Coenzyme Q10: Cardiac Function & Heart Failure
The landmark Q-SYMBIO trial demonstrated that CoQ10 supplementation (100mg twice daily) in heart failure patients reduced cardiovascular mortality by 43% and decreased hospitalizations. CoQ10 improves left ventricular ejection fraction, enhances exercise capacity, and reduces oxidative stress in cardiac tissue. Depletion is common with statin therapy and aging, making supplementation particularly relevant for cardiovascular risk reduction. Our 150mg dose provides therapeutic levels validated in clinical research.
Mortensen et al., JACC Heart Failure 2014 (Q-SYMBIO, PMID: 25282031) | Sharma et al., Circulation Heart Failure 2016 | Fotino et al., Front Biosci 2013
Magnesium: Blood Pressure & Vascular Function
Meta-analyses of randomized controlled trials confirm that magnesium supplementation produces dose-dependent reductions in both systolic (-4.18 mmHg) and diastolic (-2.27 mmHg) blood pressure. Magnesium acts as a natural calcium channel blocker, promotes endothelial nitric oxide production, and reduces vascular resistance. Our chelated bisglycinate form offers superior bioavailability compared to oxide or citrate forms. Magnesium deficiency affects over 50% of adults and is associated with increased cardiovascular mortality.
Zhang et al., Hypertension 2016 (PMID: 27402922) | Rosanoff et al., Nutrients 2021 | Fang et al., Am J Clin Nutr 2016 | Costello et al., Nutrients 2016
Vitamin D3 & K2: Arterial Calcification Prevention
The Rotterdam Study demonstrated that higher vitamin K2 intake reduced coronary calcification by 52% and cardiovascular mortality by 57% over 7-10 years. K2 (menaquinone-7) activates matrix Gla-protein (MGP), which inhibits vascular calcification—a key predictor of cardiovascular events. Combined with vitamin D3 (which increases calcium absorption), this synergy optimizes calcium metabolism, directing it to bones while preventing arterial deposition. Our 180mcg K2-MK7 dose matches levels shown effective in clinical trials.
Geleijnse et al., J Nutr 2004 (Rotterdam Study, PMID: 15051869) | Knapen et al., Thromb Haemost 2015 | Theuwissen et al., Thromb Haemost 2012
Alpha-Lipoic Acid: Endothelial Function & Oxidative Stress
Alpha-lipoic acid improves endothelial function by increasing nitric oxide bioavailability and reducing oxidative stress. Clinical trials show ALA (300-600mg daily) improves flow-mediated dilation (FMD), reduces inflammatory markers (CRP, IL-6), and enhances insulin sensitivity. As both a lipophilic and hydrophilic antioxidant, ALA protects against lipid peroxidation in cell membranes while regenerating vitamins C and E. Our 150mg dose combined with magnesium provides synergistic vascular protection.
Heinisch et al., Atherosclerosis 2010 | Sola et al., Free Radic Biol Med 2005 | Ziegler et al., Diabetes Care 2011 | Shay et al., Nutr Rev 2009
Magnesium + Vitamin D: Critical Cofactor Relationship
Magnesium is required for all enzymes that metabolize vitamin D, including 25-hydroxylase and 1-alpha-hydroxylase which convert D3 to its active form. Clinical studies show that vitamin D supplementation without adequate magnesium may not effectively raise 25(OH)D levels and can actually worsen magnesium deficiency. Conversely, magnesium supplementation enhances vitamin D status. This formula provides optimal magnesium to ensure vitamin D3 activation—a critical interaction often overlooked in cardiovascular supplementation.
Uwitonze & Razzaque, J Am Osteopath Assoc 2018 | Deng et al., BMC Med 2013 | Dai et al., Am J Clin Pathol 2016
CoQ10 + Statins: Restoration of Depleted Levels
Statin medications inhibit HMG-CoA reductase, the same enzyme pathway that produces CoQ10, leading to 25-50% depletion of endogenous CoQ10. This depletion is implicated in statin-associated muscle symptoms and may limit cardiovascular benefits. Multiple studies demonstrate that CoQ10 supplementation (100-200mg daily) restores levels, reduces muscle symptoms, and may enhance cardiovascular outcomes in statin users. This makes CoQ10 supplementation particularly important for the millions of Australians on statin therapy.
Banach et al., Arch Med Sci 2015 | Qu et al., Med Sci Monit 2018 | Caso et al., Am J Cardiol 2007 | Littarru & Langsjoen, BioFactors 2007